Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.18 HKD | +0.86% | +0.99% | -36.39% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 3.3 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.39% | 1.41B | - | ||
+40.80% | 53.67B | B- | ||
+34.92% | 38.86B | A | ||
-8.05% | 38.76B | B | ||
-8.98% | 27.27B | C | ||
+10.69% | 25.91B | B- | ||
-16.21% | 20.29B | B | ||
+31.00% | 12.78B | B+ | ||
+28.51% | 12.18B | C+ | ||
-1.67% | 11.96B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603127 Stock
- 6127 Stock
- Ratings Joinn Laboratories(China)Co.,Ltd.